Drug Search Results
More Filters [+]

EVX-020

Alternative Names: EVX-020, EVX020, EVX 020
Latest Update: None
Latest Update Note: None

Product Description

EVX-020, Sole-in-class KIF20A inhibitor - Next generation ADC payload. A selective KIF20A inhibitor to tackle highly proliferative cancers. By combining the great efficacy and broad therapeutic scope of chemotherapy and the safety potential of targeted therapy, the KIF20A inhibitor EVX-020 (formerly DIACC2010) brings chemotherapy in the era of precision medicine. Non-clinical efficacy was established in acute myeloid leukemia models. (Sourced from: https://www.evextabio.com/rd-programs/evx-020-sole-class-kif20a-inhibitor-next-generation-adc-payload)

Mechanisms of Action: KIF20A Inhibitor

Novel Mechanism: Yes

Modality: Antibody Drug Conjugate

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Evexta
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for EVX-020

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 0: Acute Myeloid Leukemia

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events

Date

Type

Title